birth. On the other hand, DGAT1 deficient mice are viable (Yen *et al., J. Lipid Research,* 2008, 49, 2283).

Despite this perinatal lethal phenotype, the metabolic role of DGAT2 has been mostly understood from effort exploiting anti-sense oligonucleotides (ASO) in rodents. In this setting, DGAT2 knockdown in *ob/ob* mice with a DGAT2 gene-specific ASO resulted in a dose dependent decrease in very low density lipoprotein ("VLDL") and a reduction in plasma TG, total cholesterol, and ApoB (Liu, *et al.*, *Biochim. Biophys Acta* 2008, 1781, 97). In the same study, DGAT2 antisense oligonucleotide treatment of *ob/ob* mice showed a decrease in weight gain, adipose weight and hepatic TG content. *Id.* In another study, antisense treatment of ob/ob mice improved hepatic steatosis and hyperlipidemia (Yu, *et al.*, *Hepatology*, 2005, 42, 362). Another study showed that diet-induced hepatic steatosis and insulin resistance was improved by knocking down DGAT2 in rats. These effects seem to be unique to inhibition of DGAT2, as ASO against DGAT1 did not lead to similar beneficial effects. Although the molecular mechanism behind these observations remains uncertain, the collective data suggest that suppression of DGAT2 is associated with reduced expression of lipogenic genes (SREBP1c, ACC1, SCD1, and mtGPAT) and increased expression of oxidative/thermogenic genes (CPT1, UCP2) (Choi *et al., J. Bio. Chem.*, 2007, 282, 22678).

In light of the above, inhibitors of DGAT2 are useful for treating disease related to the spectrum of metabolic syndrome such as hepatic steatosis, non-alcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.

DGAT2 inhibitor compounds are described in WO2021064590, WO2016036633, WO2016036636, WO2016036638, WO2018093696, WO2018093698, WO2013150416, US20150259323, WO2015077299, WO2017011276, WO2018033832, US201801628, WO2003053363.

SUMMARY

The present disclosure relates to compounds represented by Formula **I**:



I

as well as pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors.

In one aspect, there is provided a compound of Formula I:



I ,

or a pharmaceutically acceptable salt thereof wherein:

X, Y, and Z are independently selected from N or C(R^5);

R^1 is

(1) phenyl unsubstituted or substituted with 1, 2, or 3 R^6, or

(2) 5- or 6-membered heteroaryl containing 1, 2, 3 or 4 heteroatoms independently selected from N, O, and S, wherein the heteroaryl is unsubstituted or substituted with 1, 2, or 3 R^6, or

(3) 8- to 10- membered fused heteroaryl containing 1, 2, 3 heteroatoms independently selected from N, O, and S, wherein the heteroaryl is unsubstituted or substituted with 1, 2, or 3 R^6;

R^2 is

(1) phenyl unsubstituted or substituted with 1, 2, or 3 R^7,

(2) 5- or 6-membered heteroaryl containing 1, 2 or 3 heteroatoms independently selected from N, O, and S, wherein the heteroaryl is unsubstituted or substituted with 1, 2, or 3 R^7,

(3) $C_{1\text{-}6}$alkyl unsubstituted or optionally mono-substituted or disubstituted with halogen, OH, CF_3, or CN,

(4) ($C_{3\text{-}6}$)cycloalkyl unsubstituted or optionally mono-substituted or disubstituted with $C_{1\text{-}3}$alkyl, halogen, OH, CF_3, or -CN,

(5) -($C_{3\text{-}6}$)alkylC(O)NH_2,

(6) 4- to 6- membered heterocyclyl containing 1 or 2 heteroatoms independently selected from N, O and S wherein the heterocyclyl is unsubstituted or substituted by 1, 2, or 3 R^7,

(7) -CH_2-aryl unsubstituted or substituted by 1, 2, or 3 R^7,

(8) -SO_2($C_{1\text{-}6}$)alkyl unsubstituted or substituted with 1, 2, or 3 R^7, or

(9) -SO_2-aryl unsubstituted or substituted with 1, 2, or 3 R^7;

R^3 is

(1) 4- to 7-membered heterocyclyl containing 1, 2, or 3 heteroatoms independently selected from N, O and S,

(2) 5- or 6-membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from N, O, and S,

(3) -(C_{1-6})alkyl-heteroaryl, wherein the heteroaryl is a 5- or 6-membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from N, O and S,

(4) -(C_{1-6})alkyl-aryl,

(5) -(C_{1-6})alkyl-heterocyclyl, wherein the heterocyclyl is a 3- to 6-membered ring containing 1 or 2 heteroatoms independently selected from N, O and S,

(6) -(C_{1-6})alkyl,

(7) -(C_{3-6})cycloalkyl,

(8) -(C_{1-6})hydroxyalkyl,

(9) -(C_{1-6})alkyl-$S(O)_2$-$NR^{8a}R^{8b}$, or

(10) -(C_{1-6})alkyl-$S(O)_2$-(C_{1-3})alkyl,

wherein each aryl, fused aryl, heteroaryl, cycloalkyl, or heterocyclyl is unsubstituted or substituted with 1, 2, or 3 R^9, and wherein each alkyl is unsubstituted or substituted with 1, 2, or 3 R^{10};

R^4 is

(1) hydrogen, or

(2) (C_{1-3})alkyl,

or R^3 and R^4 combine along with the nitrogen atom to which they are attached to form a mono- or bicyclic heterocyclyl ring containing 1 or 2 heteroatoms independently selected from N, O and S, wherein the heterocyclyl ring is unsubstituted or substituted by 1, 2, or 3 R^{11},

when present, each R^5 is selected from

(1) hydrogen,

(2) (C_{1-6})alkyl,

(3) (C_{3-6})cycloalkyl,

(4) (C_{1-6})haloalkyl,

(5) cyano, or

(6) halogen,

when present, each R^6 is independently selected from

(1) cyano,

(2) halogen,

(3) -OC_{1-6}alkyl,

(4) (C_{3-6})cycloalkyl, optionally substituted with halogen, C_{1-3}alkyl, C_{1-6}haloalkyl, or OH,

(5) -C(=O)NH_2,

(6) -O(C_{3-6}) cycloalkyl wherein the cycloalkyl is optionally substituted with halogen, C_{1-3}alkyl, or OH,

(7) hydroxy,

(8) N(R^{11})$_2$,

(9) (C_{1-6})haloalkyl-,

(10) -O(C_{1-6})haloalkyl-,

(11) -SO_2(C_{1-6})alkyl,

(12) -SO_2NH(C_{1-6})alkyl,

(13) -SC_{1-6}alkyl,

(14) N(R^{11})C(O)R^{11},

(15) -SC_{1-6}haloalkyl, or

(16) (C_{1-6})alkyl;

when present, each R^7 is independently selected from

(1) (C_{1-3})alkyl,

(2) halogen,

(3) (C_{1-6})alkoxy-,

(4) (C_{1-6})haloalkyl-, or

(5) hydroxy;

when present, R^{8a} and R^{8b} are independently selected from

(1) hydrogen,

(2) (C_{1-3})alkyl, or

(3) (C_{3-7})cycloalkyl;

when present, each R^9 is independently selected from

(1) (C_{1-3})alkyl,

(2) (C_{1-3})haloalkyl-,

(3) oxo,

(4) (C_{3-6})cycloalkyl,

(5) $N(R^{11})_2$,

(6) hydroxy,

(7) (C_{1-3})alkoxyl-,

(8) cyano, or

(9) halogen;

when present, R^{10} is independently selected from

(1) (C_{1-3})alkoxy-,

(2) hydroxy,

(3) halogen,

(4) (C_{1-3})haloalkyl-, or

(5) $N(R^{11})_2$;

R^{11}, when present, is independently

(1) hydrogen, or

(2) (C_{1-3})alkyl.

In another aspect, there is provided a compound selected from:


,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

5
,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

, or a pharmaceutically acceptable salt thereof.

Also provided are methods of making compounds of Formula **I**, pharmaceutical compositions comprising compounds of Formula **I**, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula **I** to a patient in need thereof.

In another aspect, there is provided a composition for use in treating a condition selected from hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases and heart failure comprising a compound as defined herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically carrier.

In another aspect, there is provided use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a condition selected from hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases and heart failure.

DETAILED DESCRIPTION OF THE INVENTION

Formula I

The present disclosure is directed to compounds having structural Formula **I**:



I

or pharmaceutically acceptable salts thereof wherein:

X, Y, and Z are independently selected from N or C(R^5);

R^1 is

(1) phenyl unsubstituted or substituted with 1, 2, or 3 R^6, or

(2) 5- or 6-membered heteroaryl containing 1, 2, 3 or 4 heteroatoms independently selected from N, O, and S, wherein the heteroaryl is unsubstituted or substituted with 1, 2, or 3 R^6, or

(3) 8- to 10- membered fused heteroaryl containing 1, 2, 3 heteroatoms independently selected from N, O, and S, wherein the heteroaryl is unsubstituted or substituted with 1, 2, or 3 R^6;

R^2 is

(1) phenyl unsubstituted or substituted with 1, 2, or 3 R^7,

(2) 5- or 6-membered heteroaryl containing 1, 2 or 3 heteroatoms independently selected from N, O, and S, wherein the heteroaryl is unsubstituted or substituted with 1, 2, or 3 R^7,

(3) C_{1-6}alkyl unsubstituted or optionally mono-substituted or disubstituted with halogen, OH, CF_3, or -CN,

WHAT IS CLAIMED IS:

1. A compound of Formula I:



I ,

or a pharmaceutically acceptable salt thereof wherein:

X, Y, and Z are independently selected from N or C(R^5);

R^1 is

(1) phenyl unsubstituted or substituted with 1, 2, or 3 R^6, or

(2) 5- or 6-membered heteroaryl containing 1, 2, 3 or 4 heteroatoms independently selected from N, O, and S, wherein the heteroaryl is unsubstituted or substituted with 1, 2, or 3 R^6, or

(3) 8- to 10- membered fused heteroaryl containing 1, 2, 3 heteroatoms independently selected from N, O, and S, wherein the heteroaryl is unsubstituted or substituted with 1, 2, or 3 R^6;

R^2 is

(1) phenyl unsubstituted or substituted with 1, 2, or 3 R^7,

(2) 5- or 6-membered heteroaryl containing 1, 2 or 3 heteroatoms independently selected from N, O, and S, wherein the heteroaryl is unsubstituted or substituted with 1, 2, or 3 R^7,

(3) $C_{1\text{-}6}$alkyl unsubstituted or optionally mono-substituted or disubstituted with halogen, OH, CF_3, or CN,

(4) ($C_{3\text{-}6}$)cycloalkyl unsubstituted or optionally mono-substituted or disubstituted with $C_{1\text{-}3}$alkyl, halogen, OH, CF_3, or -CN,

(5) -($C_{3\text{-}6}$)alkylC(O)NH_2,

(6) 4- to 6- membered heterocyclyl containing 1 or 2 heteroatoms independently selected from N, O and S wherein the heterocyclyl is unsubstituted or substituted by 1, 2, or 3 R^7,

(7) -CH_2-aryl unsubstituted or substituted by 1, 2, or 3 R^7,

(8) -SO_2($C_{1\text{-}6}$)alkyl unsubstituted or substituted with 1, 2, or 3 R^7, or

(9) -SO_2-aryl unsubstituted or substituted with 1, 2, or 3 R^7;

R^3 is

(1) 4- to 7-membered heterocyclyl containing 1, 2, or 3 heteroatoms independently selected from N, O and S,

(2) 5- or 6-membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from N, O, and S,

(3) -(C_{1-6})alkyl-heteroaryl, wherein the heteroaryl is a 5- or 6-membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from N, O and S,

(4) -(C_{1-6})alkyl-aryl,

(5) -(C_{1-6})alkyl-heterocyclyl, wherein the heterocyclyl is a 3- to 6-membered ring containing 1 or 2 heteroatoms independently selected from N, O and S,

(6) -(C_{1-6})alkyl,

(7) -(C_{3-6})cycloalkyl,

(8) -(C_{1-6})hydroxyalkyl,

(9) -(C_{1-6})alkyl-$S(O)_2$-$NR^{8a}R^{8b}$, or

(10) -(C_{1-6})alkyl-$S(O)_2$-(C_{1-3})alkyl,

wherein each aryl, fused aryl, heteroaryl, cycloalkyl, or heterocyclyl is unsubstituted or substituted with 1, 2, or 3 R^9, and wherein each alkyl is unsubstituted or substituted with 1, 2, or 3 R^{10};

R^4 is

(1) hydrogen, or

(2) (C_{1-3})alkyl,

or R^3 and R^4 combine along with the nitrogen atom to which they are attached to form a mono- or bicyclic heterocyclyl ring containing 1 or 2 heteroatoms independently selected from N, O and S, wherein the heterocyclyl ring is unsubstituted or substituted by 1, 2, or 3 R^{11},

when present, each R^5 is selected from

(1) hydrogen,

(2) (C_{1-6})alkyl,

(3) (C_{3-6})cycloalkyl,

(4) (C_{1-6})haloalkyl,

(5) cyano, or

(6) halogen,

when present, each R^6 is independently selected from

(1) cyano,

(2) halogen,

(3) -OC_{1-6}alkyl,

(4) (C_{3-6})cycloalkyl, optionally substituted with halogen, C_{1-3}alkyl, C_{1-6}haloalkyl, or OH,

(5) -C(=O)NH_2,

(6) -O(C_{3-6}) cycloalkyl wherein the cycloalkyl is optionally substituted with halogen, C_{1-3}alkyl, or OH,

(7) hydroxy,

(8) N(R^{11})$_2$,

(9) (C_{1-6})haloalkyl-,

(10) -O(C_{1-6})haloalkyl-,

(11) -SO_2(C_{1-6})alkyl,

(12) -SO_2NH(C_{1-6})alkyl,

(13) -SC_{1-6}alkyl,

(14) N(R^{11})C(O)R^{11},

(15) -SC_{1-6}haloalkyl, or

(16) (C_{1-6})alkyl;

when present, each R^7 is independently selected from

(1) (C_{1-3})alkyl,

(2) halogen,

(3) (C_{1-6})alkoxy-,

(4) (C_{1-6})haloalkyl-, or

(5) hydroxy;

when present, R^{8a} and R^{8b} are independently selected from

(1) hydrogen,

(2) (C_{1-3})alkyl, or

(3) (C_{3-7})cycloalkyl;

when present, each R^9 is independently selected from

(1) (C_{1-3})alkyl,

(2) (C_{1-3})haloalkyl-,

(3) oxo,

(4) (C_{3-6})cycloalkyl,

(5) N(R^{11})$_2$,

(6) hydroxy,

(7) (C_{1-3})alkoxyl-,

(8) cyano, or

(9) halogen;

when present, R^{10} is independently selected from

(1) (C_{1-3})alkoxy-,

(2) hydroxy,

(3) halogen,

(4) (C_{1-3})haloalkyl-, or

(5) $N(R^{11})_2$;

R^{11}, when present, is independently

(1) hydrogen, or

(2) (C_{1-3})alkyl.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is

(a) phenyl optionally substituted with one to three substituents independently selected from halogen, hydroxy, CN, C_{1-3}alkyl, C_{1-3}haloalkyl, C_{3-6}cycloalkyl, OC_{1-3}alkyl, OC_{1-3}haloalkyl, OC_{3-6}cycloalkyl, $NHC(O)C_{1-3}$alkyl, $N(CH_3)_2$, $C(O)NH_2$, $-SC_{1-3}$alkyl, $S(O)_2NHC_{1-3}$alkyl, $-SC_{1-3}$haloalkyl, or $S(O)_2C_{1-3}$alkyl, and wherein the cycloalkyl is optionally independently substituted with 1-3 halogen or OH;

(b) 6 membered heteroaryl containing one or two nitrogen atoms optionally substituted with one to three substituents independently selected from halogen, hydroxy, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{3-6}cycloalkyl, OC_{1-3}alkyl, OC_{1-3}haloalkyl, O-C_{3-6}cycloalkyl, or CN, and when the cycloalkyl is cyclopropyl, the cyclopropyl is optionally substituted with halogen, or OH; or

(c) 8- to 10- membered fused heteroaryl containing 1, 2, 3 heteroatoms independently selected from N, O, and S, wherein the heteroaryl is unsubstituted or substituted with one substituent selected from halogen, (C_{1-3})alkyl, (C_{3-6})cycloalkyl, (C_{1-3})haloalkyl-, OH or OC_{1-3}alkyl.

3. The compound of any one of claims 1-2, or a pharmaceutically acceptable salt thereof, wherein R^1 is

(a) phenyl optionally substituted with one to three substituents independently selected from halogen, OH, C_{1-3}alkyl, C_{1-3}haloalkyl, C_{3-6}cycloalkyl, O-C_{3-6}cycloalkyl, CN, NHC(O)C_{1-3}alkyl, N$(CH_3)_2$, C(O)NH_2, SC_{1-3}alkyl, S$(O)_2$NHC_{1-3}alkyl, S$(O)_2C_{1-3}$alkyl, OC_{1-3}alkyl, or OC_{1-3}haloalkyl, wherein the cycloalkyl is additionally optionally substituted with 1-3 halogen;

(b) pyridyl optionally substituted with one to three substituents independently selected from halogen, C_{1-3}alkyl, C_{3-6}cycloalkyl, OC_{1-3}alkyl, or OC_{1-3}haloalkyl; or

(c) 8- to 10- membered fused heteroaryl containing 1, 2, 3 heteroatoms independently selected from N, O, and S, wherein the heteroaryl is unsubstituted or substituted with one substituent selected from halogen, (C_{1-3})alkyl, (C_{3-6})cycloalkyl, (C_{1-3})haloalkyl-, OH or OC_{1-3}alkyl.

4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein R^1 is

(a) phenyl optionally substituted with one to three substituents independently selected from F, OH, CF_3, CN, N$(CH_3)_2$, C(O)NH_2, SCH_3, S$(O)_2$NHCH_3, S$(O)_2CH_3$, OCH_2CH_3, O$CH(CH_3)_2$, OCHF_2, OCH_2CHF_2, OCF_3, OCF_2CHF_2, NHC(O)CH_3, cyclopropyl, or O-cyclopropyl, wherein the cyclopropyl is additionally optionally substituted with 1-3 F;

(b) pyridyl optionally substituted with one to three substituents independently selected from F, OC$(F)_2(CH_3)$, OCH_2CH_3, O$CH(CH_3)_2$, OCHF_2, OCH_2CHF_2, OCF_3, OCF_2CHF_2, or cyclopropyl; or

(c) 8-10 membered fused heteroaryl containing one to three heteroatoms selected from N, O, or S atom optionally substituted with CH_3.

5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein R^1 is





6. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R^1 is a phenyl unsubstituted or substituted with 1, 2, or 3 substituents independently selected from F, CF_3, CN, $N(CH_3)_2$, $C(O)NH_2$, SCH_3, $S(O)_2NHCH_3$, $S(O)_2CH_3$, $OCHF_2$, OCF_3, $OCH(CH_3)(CH_3)$, OCF_2CHF_2, OCH_2CHF_2, OCH_2CH_3, $NHC(O)CH_3$, cyclopropyl, or O-cyclopropyl, wherein the cyclopropyl is additionally optionally substituted with one to three halogen atoms.

7. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R^1 is a 6-membered heteroaryl containing 1 N and wherein the heteroaryl is unsubstituted or substituted with 1 or 2 substituents independently selected from F, $OC(F)_2(CH_3)$, OCH_2CH_3, $OCH(CH_3)_2$, $OCHF_2$, OCH_2CHF_2, OCF_3, OCF_2CHF_2, or cyclopropyl.

8. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R^1 is 

9. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein R^2 is $C_{1\text{-}6}$alkyl, $C_{3\text{-}6}$cycloalkyl, $C_{1\text{-}6}$alkylOH, $C_{1\text{-}6}$haloalkyl,

phenyl, C_{3-6}heterocycle, C_{3-6}alkylC(O)NH_2, S(O)$_2$-phenyl, or C_{1-6}alkyl-phenyl, wherein the alkyl is optionally substituted with 1-3 halogens or CF_3, and wherein the phenyl is optionally substituted with halogen.

10. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein R^2 is C_{1-6}alkyl optionally mono-substituted, or disubstituted with halogen, OH, or CF_3.

11. The compound of any one of claims 1-10, or a pharmaceutically acceptable salt thereof, wherein R^2 is C_{3-6}cycloalkyl.

12. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein R^2 is .

13. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein R^2 is .

14. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein R^3 is

(a) 4- to 7-membered heterocyclyl containing 1, 2 or 3 heteroatoms independently selected from N, O and S,

(b) 5- or 6-membered heteroaryl containing 1, 2 or 3 heteroatoms independently selected from N, O, and S,

(c) -(C_{1-6})alkyl-heteroaryl, wherein the heteroaryl is a 5- or 6-membered heteroaryl containing 1, 2 or 3 heteroatoms independently selected from N, O and S,

(d) -(C_{1-6})alkyl-aryl,

(e) -(C_{1-6})alkyl-heterocyclyl, wherein the heterocyclyl is a 3- to 6-membered ring containing 1 or 2 heteroatoms independently selected from N, O and S,

(f) -(C_{1-6})alkyl,

(g) -(C_{3-6})cycloalkyl, or

(h) (C_{1-6})hydroxyalkyl,

wherein each aryl, heteroaryl, cycloalkyl, or heterocyclyl is unsubstituted or substituted with 1, 2, or 3 R^9, and wherein each alkyl is unsubstituted or substituted with 1, 2, or 3 R^{10}.

15. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein R^3 is

a 4 to 6 membered heterocyclyl containing 1 sulfur atom optionally mono-substituted, disubstituted, or trisubstituted with halogen, C_{1-3}alkyl, or oxo.

16. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein R^3 is

(a) 4 to 6 membered cycloalkyl optionally mono-substituted, disubstituted, or trisubstituted with F, CH_3, or OH,

(b) 4 to 6 membered heterocyclyl containing 1 sulfur atom optionally mono-substituted, disubstituted, or trisubstituted with oxo, CHF_2, or CH_3,

(c) 5 or 6 membered heterocyclyl containing 1 oxygen atom optionally mono-substituted, disubstituted, or trisubstituted with CH_3, or OH,

(d) C_{1-6}alkyl-heterocyclyl, wherein the heterocyclyl is a 5 membered-heterocyclyl containing 1 oxygen atom optionally mono-substituted, disubstituted, or trisubstituted with OH,

(e) C_{1-6}alkyl-heteroaryl, wherein the heteroaryl contains 2 nitrogen atoms optionally mono-substituted, disubstituted, or trisubstituted with CH_3, or CH_2CH_3,

(f) 5 membered heteroaryl containing 2 nitrogen atoms and 1 sulfur atoms optionally mono-substituted, disubstituted, or trisubstituted with CH_3, or

(g) (g) C_{1-6}alkyl, wherein the alkyl is optionally mono-substituted, disubstituted, or trisubstituted with OH.

17. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein R^3 is



18. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein R^3 is .

19. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein R^4 is H.

20. The compound of any one of claims 1-19, or a pharmaceutically acceptable salt thereof, wherein R^5 is H, halogen, or CN.

21. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R^5 is H, F, Cl, or CN.

22. The compound of any one of claims 1, 8-21, or a pharmaceutically acceptable salt thereof, wherein R^6 is halogen, hydroxy, CN, C_{1-3}alkyl, C_{1-3}haloalkyl, C_{3-6}cycloalkyl, OC_{1-3}alkyl, OC_{1-3}haloalkyl, OC_{3-6}cycloalkyl, $S(O)_2C_{1-3}$alkyl, $NHC(O)C_{1-3}$alkyl, N $(CH_3)_2$, $C(O)NH_2$, SC_{1-6}alkyl, or $S(O)_2NHC_{1-6}$alkyl, and wherein the cycloalkyl is optionally substituted with halogen.

23. The compound of any one of claims 1, 8-21, or a pharmaceutically acceptable salt thereof, wherein R^6 is F, CF_3, $OCHF_2$, OCF_3, OCH_2CH_3, $OCH(CH_3)_2$, OCF_2CHF_2, cyclopropyl, O-cyclopropyl, CN, $N(CH_3)_2$, $C(O)NH_2$, SCH_3, $S(O)_2NHCH_3$, $NHC(O)CH_3$, OH, OCF_2CHF_2, or $S(O)_2CH_3$, and wherein the cyclopropyl is additionally optionally substituted with one to three halogen atoms.

24. The compound of any one of claims 1-8, 14-23, or a pharmaceutically acceptable

salt thereof, wherein R^7 is F, CF_3, or OH.

25. The compound of any one of claims 1-14, 19-24, or a pharmaceutically acceptable salt thereof, wherein R^9 is =O, OH, $C_{1\text{-}3}$alkyl, $C_{1\text{-}3}$haloalkyl, or halogen.

26. The compound of any one of claims 1-14, 19-25, or a pharmaceutically acceptable salt thereof, wherein R^9 is =O, OH, CH_3, CH_2CH_3, F, CF_3, or CHF_2.

27. The compound of any one of claims 1-14, 19-26, or a pharmaceutically acceptable salt thereof, wherein R^{10} is OH.

28. The compound of any one of claims 1-14, 19-27, or a pharmaceutically acceptable salt thereof, wherein R^{10} is OH, F, or CF_3.

29. The compound of any one of claims 1-28, or a pharmaceutically acceptable salt thereof, wherein X is N, Y is $C(R^5)$, and Z is $C(R^5)$.

30. The compound of any one of claims 1-28, or a pharmaceutically acceptable salt thereof, wherein X is $C(R^5)$, Y is N, and Z is $C(R^5)$.

31. The compound of any one of claims 1-28, or a pharmaceutically acceptable salt thereof, wherein X is $C(R^5)$, Y is $C(R^5)$ and Z is N.

32. The compound of any one of claims 1-28, or a pharmaceutically acceptable salt thereof, wherein X, Y, and Z are $C(R^5)$.

33. The compound of any one of claims 1-32, or a pharmaceutically acceptable salt thereof, which is


, 
, 
, 
, or


.

34. The compound of any one of claims 1-32, or a pharmaceutically acceptable salt thereof, which is


,

,

, or

.

35. A compound selected from:


,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,




,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

or a pharmaceutically acceptable salt thereof.

36. The compound of any one of claims 1-35, or a pharmaceutically acceptable salt thereof, which is

(*R*)-1,3-bis(4-fluorophenyl)-*N*-(3-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[d]imidazole-5-carboxamide,

1-(3-(difluoromethoxy)phenyl)-3-(4-fluorophenyl)-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
(*R*)-1-(3-(difluoromethoxy)phenyl)-3-(4-fluorophenyl)-*N*-(3-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
3-(3-(difluoromethoxy)phenyl)-1-(4-fluorophenyl)-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-2,3-dihydro-1*H*-imidazo[4,5-*b*]pyridine-6-carboxamide,
1-(2-(Difluoromethoxy)-5-fluoropyridin-4-yl)-3-isopropyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
1-(3-isopropoxyphenyl)-3-isopropyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-benzimidazole-5-carboxamide,
3-isopropyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-1-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]benzimidazole-5-carboxamide,
1-[3-(2,2-difluoroethoxy)phenyl]-3-isopropyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-benzimidazole-5-carboxamide,
1-(3-ethoxyphenyl)-3-isopropyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-benzimidazole-5-carboxamide,
3-isopropyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-2-oxo-1-[3-(trifluoromethoxy)phenyl]benzimidazole-5-carboxamide,
1-[3-(2,2-difluoroethoxy)phenyl]-3-isopropyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-2-oxo-benzimidazole-5-carboxamide,
1-[4-(difluoromethoxy)-2-pyridyl]-3-isopropyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-benzimidazole-5-carboxamide,
1-(3-cyclopropylphenyl)-3-isopropyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-benzimidazole-5-carboxamide,
1-[3-(cyclopropoxy)phenyl]-3-isopropyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-benzimidazole-5-carboxamide,
1-(2-Ethoxy-5-fluoropyridin-4-yl)-3-isopropyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
1-(2-ethoxy-5-fluoropyridin-4-yl)-3-isopropyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
(*S*)-1-(2-Ethoxy-5-fluoropyridin-4-yl)-3-isopropyl-*N*-(3-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
(*R*)-1-(2-Ethoxy-5-fluoropyridin-4-yl)-3-isopropyl-*N*-(3-methyl-1,1-dioxidotetrahydrothiophen-

3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
3-isopropyl-N-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-1-[3-(trifluoromethoxy)phenyl]benzimidazole-5-carboxamide,
1-(2-(difluoromethoxy)-5-fluoropyridin-4-yl)-3-isopropyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
1-(2-Ethoxy-5-fluoropyridin-4-yl)-6-fluoro-3-isopropyl-N-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
1-(3-(2,2-Difluorocyclopropyl)phenyl)-3-isopropyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
(*R*)-1-(3-(Difluoromethoxy)phenyl)-3-isopropyl-N-(3-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
1-(2-(Difluoromethoxy)-5-fluoropyridin-4-yl)-6-fluoro-3-isopropyl-N-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-3-isopropyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
1-[3-(difluoromethoxy)phenyl]-3-isopropyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-benzimidazole-5-carboxamide,
1-[3-(difluoromethoxy)phenyl]-*N*-(2-hydroxy-1,2-dimethyl-propyl)-3-isopropyl-2-oxo-benzimidazole-5-carboxamide,
1-[3-(difluoromethoxy)phenyl]-*N*-[(1*S*,2*S*)-2-hydroxycyclopentyl]-3-isopropyl-2-oxo-benzimidazole-5-carboxamide,
1-[3-(difluoromethoxy)phenyl]-N-[(3*R*,4*S*)-3-hydroxytetrahydropyran-4-yl]-3-isopropyl-2-oxo-benzimidazole-5-carboxamide,
N-[(1S,2R)-3,3-difluoro-2-hydroxy-cyclohexyl]-1-[3-(difluoromethoxy)phenyl]-3-isopropyl-2-oxo-benzimidazole-5-carboxamide,
1-[3-(difluoromethoxy)phenyl]-*N*-[(1*R*,2*R*)-2-hydroxycyclohexyl]-3-isopropyl-2-oxo-benzimidazole-5-carboxamide,
1-[3-(difluoromethoxy)phenyl]-3-isopropyl-*N*-[(3*S*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-benzimidazole-5-carboxamide,
1-[3-(difluoromethoxy)phenyl]-*N*-(3,3-difluoro-1-methyl-cyclobutyl)-3-isopropyl-2-oxo-benzimidazole-5-carboxamide,
1-[3-(difluoromethoxy)phenyl]-*N*-[(1*S*)-1-(hydroxymethyl)-2-methyl-propyl]-3-isopropyl-2-oxo-benzimidazole-5-carboxamide,

1-[3-(difluoromethoxy)phenyl]-*N*-[(1*S*,2*S*)-2-hydroxycyclohexyl]-3-isopropyl-2-oxo-benzimidazole-5-carboxamide,

1-(3-(difluoromethoxy)phenyl)-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-3-(tetrahydro-2*H*-pyran-4-yl)-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,

(*R*)-3-Cyclobutyl-1-(3-(difluoromethoxy)phenyl)-*N*-(3-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,

(*R*)-3-Cyclopentyl-1-(3-(difluoromethoxy)phenyl)-*N*-(3-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,

1-(3-(Difluoromethoxy)phenyl)-3-ethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,

1-(3-(Difluoromethoxy)phenyl)-3-ethyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,

3-Cyclopropyl-1-(3-(difluoromethoxy)phenyl)-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,

1-(3-(Difluoromethoxy)phenyl)-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxo-3-(3,3,3-trifluoropropyl)-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,

1-(3-(Difluoromethoxy)phenyl)-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-3-(2,2,2-trifluoroethyl)-2,3-dihydro-1H-benzo[*d*]imidazole-5-carboxamide,

1-(3-(difluoromethoxy)phenyl)-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxo-3-(2,2,2-trifluoroethyl)-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,

1-(3-(Difluoromethoxy)phenyl)-3-(1,1-difluoropropan-2-yl)-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxo-2,3-dihydro-1*H*-benzo[d]imidazole-5-carboxamide,

1-(3-(Difluoromethoxy)phenyl)-3-(1,1-difluoropropan-2-yl)-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxo-2,3-dihydro-1*H*-benzo[d]imidazole-5-carboxamide,

3-(*sec*-butyl)-1-(3-(difluoromethoxy)phenyl)-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,

3-(*sec*-butyl)-1-(3-(difluoromethoxy)phenyl)-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,

1-(4-acetamido-3-hydroxyphenyl)-3-isopropyl-N-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,

3-isopropyl-N-(3-methyl-1,1-dioxidothietan-3-yl)-1-(2-methylbenzo[d]oxazol-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,

3-isopropyl-N-(3-methyl-1,1-dioxidothietan-3-yl)-1-(2-methylbenzo[d]oxazol-6-yl)-2-oxo-2,3-

dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(3-fluorophenyl)-3-isopropyl-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(5-fluoro-2-isopropoxypyridin-4-yl)-3-isopropyl-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(3-cyanophenyl)-3-isopropyl-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
3-isopropyl-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(3-(dimethylamino)phenyl)-3-isopropyl-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(3-carbamoylphenyl)-3-isopropyl-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
3-isopropyl-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1-(3-(methylthio)phenyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
3-isopropyl-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1-(3-(N-methylsulfamoyl)phenyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
3-isopropyl-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1-(3-(methylsulfonyl)phenyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-3-(4-fluorobenzyl)-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-3-methyl-N-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-3-isopropyl-N-(5-methyl-1,3,4-thiadiazol-2-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-N-((3-hydroxytetrahydrofuran-3-yl)methyl)-3-isopropyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-N-((1-ethyl-1H-pyrazol-4-yl)methyl)-3-isopropyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-3-(2-hydroxy-2-methylpropyl)-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
1-(5-(difluoromethoxy)-2-fluorophenyl)-3-(3-hydroxy-3-methylbutan-2-yl)-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,

1-(5-(difluoromethoxy)-2-fluorophenyl)-3-(3-hydroxy-3-methylbutan-2-yl)-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(5-(difluoromethoxy)-2-fluorophenyl)-3-(3-hydroxy-3-methylbutan-2-yl)-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-3-(3-hydroxy-3-methylbutan-2-yl)-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-3-(3-hydroxy-3-methylbutan-2-yl)-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(3-(2,2-difluoroethoxy)phenyl)-3-(3-hydroxy-3-methylbutan-2-yl)-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(3-(2,2-difluoroethoxy)phenyl)-3-(3-hydroxy-3-methylbutan-2-yl)-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(2-ethoxy-5-fluoropyridin-4-yl)-3-(3-hydroxy-3-methylbutan-2-yl)-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(2-ethoxy-5-fluoropyridin-4-yl)-3-(3-hydroxy-3-methylbutan-2-yl)-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
6-fluoro-1-(2-fluoro-5-(trifluoromethoxy)phenyl)-3-(3-hydroxy-3-methylbutan-2-yl)-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
6-fluoro-1-(2-fluoro-5-(trifluoromethoxy)phenyl)-3-(3-hydroxy-3-methylbutan-2-yl)-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(2-fluoro-5-(trifluoromethoxy)phenyl)-3-(3-hydroxy-3-methylbutan-2-yl)-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(2-fluoro-5-(trifluoromethoxy)phenyl)-3-(3-hydroxy-3-methylbutan-2-yl)-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(2-(2,2-difluoroethoxy)-5-fluoropyridin-4-yl)-3-(3-hydroxy-3-methylbutan-2-yl)-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(2-(2,2-difluoroethoxy)-5-fluoropyridin-4-yl)-3-(3-hydroxy-3-methylbutan-2-yl)-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(5-(2,2-difluoroethoxy)-2-fluorophenyl)-3-(3-hydroxy-3-methylbutan-2-yl)-N-(4-methyl-1,1-

dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(5-(2,2-difluoroethoxy)-2-fluorophenyl)-6-fluoro-3-(3-hydroxy-3-methylbutan-2-yl)-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(2-(2,2-difluoroethoxy)-5-fluoropyridin-4-yl)-6-fluoro-3-(3-hydroxy-3-methylbutan-2-yl)-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(2-(2,2-difluoroethoxy)-5-fluoropyridin-4-yl)-6-fluoro-3-(3-hydroxy-3-methylbutan-2-yl)-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(5-(2,2-difluoroethoxy)-2-fluorophenyl)-6-fluoro-3-(3-hydroxy-3-methylbutan-2-yl)-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(5-(2,2-difluoroethoxy)-2-fluorophenyl)-6-fluoro-3-(3-hydroxy-3-methylbutan-2-yl)-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
3-(3-hydroxy-3-methylbutan-2-yl)-N-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-1-(3-(1,1,2,2-tetrafluoroethoxy)phenyl)-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
3-(3-hydroxy-3-methylbutan-2-yl)-N-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-1-(3-(1,1,2,2-tetrafluoroethoxy)phenyl)-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
3-(3-hydroxy-3-methylbutan-2-yl)-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-1-(3-(1,1,2,2-tetrafluoroethoxy)phenyl)-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
3-(3-hydroxy-3-methylbutan-2-yl)-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-1-(3-(1,1,2,2-tetrafluoroethoxy)phenyl)-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(2-ethoxy-5-fluoropyridin-4-yl)-3-(3-hydroxy-3-methylbutan-2-yl)-N-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(2-ethoxy-5-fluoropyridin-4-yl)-3-(3-hydroxy-3-methylbutan-2-yl)-N-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(5-(Difluoromethoxy)-2-fluorophenyl)-3-isopropyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
1-(5-(Difluoromethoxy)-2-fluorophenyl)-3-isopropyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
(*S*)-1-(5-(Difluoromethoxy)-2-fluorophenyl)-3-isopropyl-*N*-(3-methyl-1,1-

dioxidotetrahydrothiophen-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
(*R*)-1-(5-(Difluoromethoxy)-2-fluorophenyl)-3-isopropyl-*N*-(3-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
1-(5-(Difluoromethoxy)pyridin-3-yl)-3-isopropyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
1-(5-Cyclopropylpyridin-3-yl)-3-isopropyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
3-(1-amino-1-oxopropan-2-yl)-1-(3-(difluoromethoxy)phenyl)-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxo-3-(phenylsulfonyl)-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
1-isopropyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-2-oxo-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]imidazo[4,5-*b*]pyridine-6-carboxamide,
3-[3-(difluoromethoxy)phenyl]-1-isopropyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-2-oxo-imidazo[4,5-*b*]pyridine-6-carboxamide,
3-[3-(difluoromethoxy)phenyl]-1-isopropyl-*N*-[(3*S*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-imidazo[4,5-*b*]pyridine-6-carboxamide,
3-[3-(difluoromethoxy)phenyl]-1-isopropyl-*N*-[(3*R*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-imidazo[4,5-*b*]pyridine-6-carboxamide,
1-isopropyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-3-[3-(trifluoromethoxy)phenyl]imidazo[4,5-*b*]pyridine-6-carboxamide,
1-isopropyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-2-oxo-3-[3-(trifluoromethoxy)phenyl]imidazo[4,5-*b*]pyridine-6-carboxamide,
1-isopropyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]imidazo[4,5-*b*]pyridine-6-carboxamide,
1-isopropyl-N-[(3*S*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]imidazo[4,5-*b*]pyridine-6-carboxamide,
1-isopropyl-N-[(3*R*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]imidazo[4,5-*b*]pyridine-6-carboxamide,
3-(3-ethoxyphenyl)-1-isopropyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-imidazo[4,5-*b*]pyridine-6-carboxamide,
3-(3-ethoxyphenyl)-1-isopropyl-*N*-[(3*S*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-imidazo[4,5-*b*]pyridine-6-carboxamide,

3-(3-ethoxyphenyl)-1-isopropyl-*N*-[(3*R*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-imidazo[4,5-*b*]pyridine-6-carboxamide,
3-(3-ethoxyphenyl)-1-isopropyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-2-oxo-imidazo[4,5-*b*]pyridine-6-carboxamide,
3-(3-isopropoxyphenyl)-1-isopropyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-imidazo[4,5-*b*]pyridine-6-carboxamide,
3-(3-isopropoxyphenyl)-1-isopropyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-2-oxo-imidazo[4,5-*b*]pyridine-6-carboxamide,
3-[5-(difluoromethoxy)-2-fluoro-phenyl]-1-isopropyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-imidazo[4,5-*b*]pyridine-6-carboxamide,
3-[5-(difluoromethoxy)-2-fluoro-phenyl]-1-isopropyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-2-oxo-imidazo[4,5-*b*]pyridine-6-carboxamide,
3-[3-(difluoromethoxy)phenyl]-1-isopropyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-imidazo[4,5-*b*]pyridine-6-carboxamide,
3-(3-(difluoromethoxy)phenyl)-1-isopropyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-2,3-dihydro-1*H*-imidazo[4,5-*c*]pyridine-6-carboxamide,
3-(3-(difluoromethoxy)phenyl)-1-isopropyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxo-2,3-dihydro-1*H*-imidazo[4,5-*c*]pyridine-6-carboxamide,
1-(3-(difluoromethoxy)phenyl)-3-isopropyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-2,3-dihydro-1*H*-imidazo[4,5-*b*]pyridine-5-carboxamide,
1-[3-(difluoromethoxy)phenyl]-7-fluoro-3-isopropyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-benzimidazole-5-carboxamide,
1-[3-(difluoromethoxy)phenyl]-7-fluoro-3-isopropyl-*N*-[(3*S*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-benzimidazole-5-carboxamide,
1-[3-(difluoromethoxy)phenyl]-7-fluoro-3-isopropyl-*N*-[(3*R*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-benzimidazole-5-carboxamide,
1-[3-(difluoromethoxy)phenyl]-7-fluoro-3-isopropyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-2-oxo-benzimidazole-5-carboxamide,
1-(3-(Difluoromethoxy)phenyl)-6-fluoro-3-isopropyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
(R)-1-(3-(Difluoromethoxy)phenyl)-6-fluoro-3-isopropyl-N-(3-methyl-1,1-dioxidotetrahydrothiophen-3-l)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
(S)-1-(3-(Difluoromethoxy)phenyl)-6-fluoro-3-isopropyl-N-(3-methyl-1,1-

dioxidotetrahydrothiophen-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(2-(2,2-difluoroethoxy)-5-fluoropyridin-4-yl)-6-fluoro-3-isopropyl-N-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
1-(2-ethoxy-5-fluoropyridin-4-yl)-6-fluoro-3-isopropyl-N-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
N-(4-(difluoromethyl)-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1-(2-ethoxy-5-fluoropyridin-4-yl)-6-fluoro-3-isopropyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
6-fluoro-3-isopropyl-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-1-(4-(1,1,2,2-tetrafluoroethoxy)pyridin-2-yl)-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide
1-(4-(2,2-difluoroethoxy)pyridin-2-yl)-3-isopropyl-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
3-isopropyl-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-1-(4-(1,1,2,2-tetrafluoroethoxy)pyridin-2-yl)-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,1-(4-(2,2-difluoroethoxy)pyridin-2-yl)-6-fluoro-3-isopropyl-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide,
1-(2-(difluoromethoxy)-5-fluoropyridin-4-yl)-6-fluoro-3-isopropyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
1-(2-(difluoromethoxy)-5-fluoropyridin-4-yl)-6-fluoro-3-isopropyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
(*S*)-1-(3-(Difluoromethoxy)phenyl)-4-fluoro-3-isopropyl-*N*-(3-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
(*R*)-1-(3-(Difluoromethoxy)phenyl)-4-fluoro-3-isopropyl-*N*-(3-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
1-(3-(Difluoromethoxy)phenyl)-4-fluoro-3-isopropyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
(*S*)-6-Chloro-1-(3-(difluoromethoxy)phenyl)-3-isopropyl-*N*-(3-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide,
4-chloro-1-(3-(difluoromethoxy)phenyl)-3-isopropyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide, or
4-cyano-1-(3-(difluoromethoxy)phenyl)-3-isopropyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxamide.

37. A composition for use in treating a condition selected from hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases and heart failure comprising a compound of any of claims 1-36, or a pharmaceutically acceptable salt thereof, and a pharmaceutically carrier.

38. Use of a compound of any of claims 1-36, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a condition selected from hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases and heart failure.